Cardiac involvement, morbidity and mortality in hereditary transthyretin amyloidosis because of p.Glu89Gln mutation.
Adult
Aged
Amyloid Neuropathies, Familial
/ diagnosis
Arrhythmias, Cardiac
/ mortality
Cardiomyopathies
/ diagnosis
Cause of Death
Disease Progression
Female
Genetic Predisposition to Disease
Heart Failure
/ mortality
Humans
Male
Middle Aged
Mutation
Phenotype
Prealbumin
/ genetics
Prognosis
Prospective Studies
Risk Assessment
Risk Factors
Time Factors
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
entrez:
3
8
2020
pubmed:
3
8
2020
medline:
8
6
2021
Statut:
ppublish
Résumé
Hereditary transthyretin amyloidosis is a systemic infiltrative disease, caused by a mutation in the transthyretin gene. p.Glu89Gln is the most common mutation in the Balkan countries. We evaluated the clinical manifestations, cardiac involvement, morbidity and mortality in 78 patients with p.Glu89Gln mutation, verified through a DNA analysis. Clinical assessment, electrocardiogram and echocardiography were performed at the time of diagnosis. The patients have been followed for 30 months. All included patients were Caucasian, 39 (50%) - men, with median age at diagnosis of 56 years (42-73), median age at onset -- 53 years (35-69), starting significantly earlier in men (4.36, P = 0.004). Cardiac and neurological involvement was found in 74 (95%) patients. Pathological ECG was present in 65 (84%) patients, infarct pattern in 43 (56%), low voltage in 24 (31%). Echocardiography revealed an infiltrative cardiomyopathy with restrictive filling in 31 (40%) and ejection fraction less than 50% in 20 (27%) patients. Twenty-two patients (28%) died: 14 (64%) because of advanced heart failure, 6 (27%) died suddenly, 2 (9%) from an ischemic stroke. The median age at death was 58.5 years (52-72). No statistically significant sex difference in survival was observed; a significant difference in survival was found for the New York Heart Association class, familial amyloidotic polyneuropathy stage, ejection fraction, filling pattern and tafamidis treatment. Cardiac involvement is common and has significant prognostic implications in the evaluated patients with p.Glu89Gln mutation. Heart failure and rhythm disturbances are the main causes of death. An earlier identification of the disease is crucial to improve prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Hereditary transthyretin amyloidosis is a systemic infiltrative disease, caused by a mutation in the transthyretin gene. p.Glu89Gln is the most common mutation in the Balkan countries.
METHODS
METHODS
We evaluated the clinical manifestations, cardiac involvement, morbidity and mortality in 78 patients with p.Glu89Gln mutation, verified through a DNA analysis. Clinical assessment, electrocardiogram and echocardiography were performed at the time of diagnosis. The patients have been followed for 30 months.
RESULTS
RESULTS
All included patients were Caucasian, 39 (50%) - men, with median age at diagnosis of 56 years (42-73), median age at onset -- 53 years (35-69), starting significantly earlier in men (4.36, P = 0.004). Cardiac and neurological involvement was found in 74 (95%) patients. Pathological ECG was present in 65 (84%) patients, infarct pattern in 43 (56%), low voltage in 24 (31%). Echocardiography revealed an infiltrative cardiomyopathy with restrictive filling in 31 (40%) and ejection fraction less than 50% in 20 (27%) patients. Twenty-two patients (28%) died: 14 (64%) because of advanced heart failure, 6 (27%) died suddenly, 2 (9%) from an ischemic stroke. The median age at death was 58.5 years (52-72). No statistically significant sex difference in survival was observed; a significant difference in survival was found for the New York Heart Association class, familial amyloidotic polyneuropathy stage, ejection fraction, filling pattern and tafamidis treatment.
CONCLUSION
CONCLUSIONS
Cardiac involvement is common and has significant prognostic implications in the evaluated patients with p.Glu89Gln mutation. Heart failure and rhythm disturbances are the main causes of death. An earlier identification of the disease is crucial to improve prognosis.
Identifiants
pubmed: 32740500
doi: 10.2459/JCM.0000000000001036
pii: 01244665-202009000-00012
doi:
Substances chimiques
Prealbumin
0
TTR protein, human
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
688-695Références
Saraiva MJ, Birken S, Costa PP, Goodman DS. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type: definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 1984; 74:104–119.
Parman Y, Adams D, Obici L, et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol 2016; 29: (Suppl 1): S3–13.
Conceição I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 2007; 35:116–118.
Coelho T, Maurer MS, Suhr OB. THAOS - the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013; 29:63–76.
Kirov A, Sarafov S, Pavlova Z, et al. Founder effect of the Glu89Gln TTR mutation in the Bulgarian population. Amyloid Amyloid 2019; 26:181–185.
Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 2013; 34:520–528.
Rapezzi C, Perugini E, Salvi F, et al. Phenotypic and genotypic heterogenicity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid 2006; 13:143–153.
González-López E, López-Sainz Á, Garcia-Pavia P. Diagnosis and treatment of transthyretin cardiac amyloidosis: progress and hope. Rev Esp Cardiol (Engl Ed) 2017; 70:991–1004.
Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International SymposIum on Amyloid and Amyloidosis. Am J Hematol 2005; 79:319–328.
Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A. Forty years of experience with type I amyloid neuropathy: review of 483 cases. Amyloid and amyloidosis 1980; Amsterdam: Execerpta Medica, 88–98.
Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010; 7:398–408.
Ruberg F, Berk J. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012; 126:1286–1300.
Mor-Avi V, Lang RM, Badano LP, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications Endorsed by the Japanese Society of Echocardiography. Eur J Echocardiogr 2011; 12:167–205.
Evangelista A, Flachskampf F, Lancellotti P, et al. European Association of Echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies. Eur J Echocardiogr 2008; 9:438–448.
Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7:79–108.
Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2016; 17:1321–1360.
Yingchoncharoen T, Agarwal S, Popovi ZB, Marwick TH. Normal ranges of left ventricular strain: a meta-analysis. J Am Soc Echocardiogr 2013; 26:185–191.
Almeida MR, Ferlini A, Forabosco A, et al. Two transthyretin variants (TTR ala-49 and TTR gln-89) in two Sicilian kindreds with hereditary amyloidosis. Hum Mutat 1992; 1:211–215.
Salvi F, Ferlini A, Plasmati R, et al. Familial amyloidotic polyneuropathy in Italy. Arquivos Med 1990; 3:19–24.
Mazzeo A, Russo M, Di Bella J, et al. Transthyretin-related familial amyloid polyneuropathy (TTR-FAP): a single-center experience in Sicily, an Italian Endemic Area. J Neuromuscul Dis 2015; 2:39–48.
Durmuş-Tekçe H, Matur Z, Mert Atmaca M, et al. Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey. Neuromuscul Disord 2016; 26:441–446.
Suhr OB, Svendsen IH, Andersson R, Danielsson A, Holmgren G, Ranlov PJ. Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med 2003; 254:225–235.
Iorio A, De Angelis F, Di Girolamo M, et al. Population diversity of the genetically determined TTR expression in human tissues and its implications in TTR amyloidosis. BMC Genomics 2017; 18:254.
Polimanti R, Di Girolamo M, Manfellotto D, et al. Functional variation of the transthyretin gene among human populations and its correlation with amyloidosis phenotypes. Amyloid 2013; 20:256–262.
Iorio A, De Lillo A, De Angelis F, et al. Noncoding variants contribute to the clinical heterogeneity of TTR amyloidosis. Eur J Hum Genet 2017; 25:1055–1060.
Alves-Ferreira M, Coelho T, Santos D, et al. A Trans-acting factor may modify age at onset in familial amyloid polyneuropathy ATTRV30 M in Portugal. Mol Neurobiol 2018; 55:3676.
Yordanova I, Pavlova Z, Kirov A, et al. Monoallelic expression of the TTR gene as a contributor to the age at onset and penetrance of TTR-related amyloidosis. Gene 2019; 705:16–21.
Lindqvist P, Olofsson BO, Backman C, Suhr O, Waldenstroma A. Pulsed tissue Doppler and strain imaging discloses early signs of infiltrative cardiac disease: a study on patients with familial amyloidotic polyneuropathy. Eur J Echocardiogr 2006; 7:22–30.
Fadel B, Baldini L, Pergola V, Al Bulbul Z, Di Salvo G. Myocardial deformation imaging and rare cardiomyopathies with hypertrophic phenotype: a review focused on Fabry disease, Friedreich ataxia and amyloidosis. Cardiogenetics 2013; 3:22–27.
Saelices L, Chung K, Lee Ji H, et al. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition. PNAS 2018; 115:E6741–E6750.
Coelho T, Maia L, Martins da Silva A, et al. Tafamidis (Fx-1006A):a first-in-class disease-modifying therapy for transthyretin familial amyloid. Amyloid 2010; 17:75–76.
Donnelly JP, Hanna M. Cardiac amyloidosis: an update on diagnosis and treatment. Cleveland Clin J Med 2017; 84: (Suppl 3): 12–26.
Mathew S, Maurer, Jeffrey H, Schwartz, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379:1007–1016.